Загрузка...
Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials
PURPOSE: Clinical trials of statins and other lipid-lowering therapies (LLTs) often report large inter-individual variations in their effects on low-density lipoprotein cholesterol (LDL-C). We evaluated apparent hyporesponsiveness to the proprotein convertase subtilisin/kexin type 9 inhibitor aliroc...
Сохранить в:
| Опубликовано в: : | Cardiovasc Drugs Ther |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer US
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5958153/ https://ncbi.nlm.nih.gov/pubmed/29627892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-018-6784-z |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|